Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Enters LC-Triple Quad Market with Launch of New EVOQ Mass Specs

Premium

This story originally ran on Sept. 4.

Bruker this week launched its new triple quadrupole mass spectrometers – the EVOQ Qube and EVOQ Elite.

The instruments, which Bruker launched in conjunction with this week's 2012 Japan Analytical Scientific Instruments Show, are the company's first LC-triple quad releases and expand its offerings in the areas of targeted and clinical proteomics.

Bruker obtained triple-quad technology in 2010 when it purchased three Varian product lines – including a gas chromatography triple-quadrupole mass spec – from Agilent as part of that firm's Varian buy (PM 05/21/2010), and last year, it launched its Scion GC-triple quad platform, but until this week it had not released an LC-triple quad system for proteomics work.

Triple quadrupoles have proven key in mass spec's push toward the clinic, with triple quad-based multiple-reaction monitoring assays emerging as perhaps the most clinically promising mass spec workflow for targeted proteomics research and protein biomarker-based diagnostics.

Bruker has largely focused its clinical proteomics efforts around its MALDI-MS platforms (PM 1/20/2012), but with the release of the EVOQ machines, the company will now offers MRM-MS capabilities as well, joining competitors including AB Sciex, Agilent, Shimadzu, Thermo Fisher Scientific, and Waters.

The instruments feature vacuum-insulated probe heated ESI and active exhaust API ion sources, 14,000 amu/sec scan speeds, 25 msec positive/negative ion switching, and Bruker's lens-free mass filter design, which, the company said, allows for enhanced MRM performance.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.